Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
New drug targets Hard-to-Treat cancers after immunotherapy fails
Disease control Recruiting nowThis early-stage study tests a new drug called IL12-L19L19 in people with advanced or spreading solid tumors that no longer respond to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug shrinks tumors. About 80 adults aged 18 to 8…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
New injection before surgery may keep melanoma from coming back
Disease control Recruiting nowThis study tests whether injecting the drug Daromun into melanoma tumors before surgery can help prevent the cancer from returning. About 186 people with stage IIIB, IIIC, or IIID melanoma will either get Daromun plus standard surgery and follow-up treatment, or just standard car…
Phase: PHASE3 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New radioactive combo targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, alone or with an immune-boosting drug, in people with advanced solid tumors that have a specific marker called FAP. The main goal is to find a safe dose and check for side effects. About 56 adults whose cancer has worsened afte…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New injection targets arthritis flares in early trial
Symptom relief Recruiting nowThis early-stage study tests a new drug called F8IL10 for people with rheumatoid arthritis. The drug is injected directly into an inflamed joint to see if it is safe and to find the best dose. About 42 adults with arthritis flares will take part. The goal is to measure side effec…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated May 17, 2026 03:00 UTC